Syn2bio

Syn2Bio is a synthetic biology-driven biotechnology company based in Suzhou, China, focused on the development of next-generation protein therapeutics and vaccines. The company leverages its proprietary Syn2Bio platform, which integrates artificial intelligence, high-throughput screening, and protein engineering to design and optimize novel biologics. Their pipeline includes multi-specific antibodies and recombinant protein vaccines targeting oncology and infectious diseases. Syn2Bio aims to accelerate the drug discovery process and improve the efficacy of complex biological drugs through its modular design approach. The company has successfully raised significant funding from leading investors such as Sequoia China and Hillhouse Capital to advance its pre-clinical programs.